Novo Nordisk is no longer being priced as the unchallenged owner of the incretin category. The second-quarter print shows volume returning while American net price keeps giving ground, and that is the entire debate. Adjusted sales rose 7% at constant rates even as reported operating profit fell on a prior-year rebate reversal and a pipeline write-down. The market already treats this as a cash franchise rather than a growth compounder.
The oral Wegovy launch is the one commercial event that still looks like a franchise expansion rather than a defensive mix shift. Cumulative United States prescriptions have passed 5 million since the January debut, and weekly scripts cleared a quarter million by mid-July. That volume is arriving at a lower realized price than the old injectable book, and self-pay now accounts for about a third of American injectable Wegovy. Management raised the full-year adjusted outlook to a band from flat to a mid-single-digit decline. The raise de-risks the current year without restoring the old growth identity.
The counterargument is already visible in the product mix. Eli Lilly continues to take almost all of the incremental injectable dollar, the next-generation combination has not beaten tirzepatide in head-to-head work, and a January list-price reset still sits on the calendar. The open question is whether the pill, international volume, and the new Medicare access program rebuild earnings power before that reset lands.